scholarly journals Whole genome analysis reveals the genomic complexity in metastatic cutaneous squamous cell carcinoma

Author(s):  
Amarinder Singh Thind ◽  
Bruce Ashford ◽  
Dario Strbenac ◽  
Ruta Gupta ◽  
Jonathan R Clark ◽  
...  

Metastatic cutaneous squamous cell carcinoma (cSCC) is associated with a high risk of recurrence and poor prognosis. There is limited published data exploring whole genome sequencing (WGS). The aim of this project was to provide the first comprehensive genomic understanding of the state of metastatic cSCC. In this study, we used WGS on matched tumor and blood DNA to detect somatic genetic alterations from 25 patients with regional metastases of head and neck cSCC. Our computational analyses interrogate clinical impacts of these genetic alterations on metastatic cSCC across the cohort for both the coding and non-coding genome. In the non-coding genome, 3UTR regions of EVC (48%), PPP1R1A (48%) and LUM (16%) were significantly functionally altered (Q-value < 0.05). Further, significant functional alterations are observed in the tumor suppressing lncRNA LINC01003 ( 68% of specimens, Q-value: 0.0158). In addition, significant recurrent copy number loss in tumor suppressor genes KANSL1 and PTPRD and gain in CALR, CCND1 and FGF3 was observed for coding regions. SNVs driver analyses predicted TP53, CDKN2A, as potential drivers of the metastasis cSCC (using 3 different tools). Indel signature analysis highlight dominance of ID signature 13 followed by ID8 & ID9. Interestingly, ID 9 has previously been shown to have no association with skin melanoma, unlike ID 13 and 8, suggesting some point of difference between these two skin-based diseases. The overall landscape of variation in metastatic cSCC is dominated by cell cycle and DNA repair disruption.

Head & Neck ◽  
2010 ◽  
Vol 32 (10) ◽  
pp. 1288-1294 ◽  
Author(s):  
Ardalan Ebrahimi ◽  
Marc D. Moncrieff ◽  
Jonathan R. Clark ◽  
Kerwin F. Shannon ◽  
Kan Gao ◽  
...  

2020 ◽  
Author(s):  
Charles Lin ◽  
Trishna Ballah ◽  
Michelle Nottage ◽  
Karen Hay ◽  
Benjamin Chua ◽  
...  

Abstract Background: Patients with unresectable advanced cutaneous squamous cell carcinoma (cSCC) are generally treated with palliative intent. Immune checkpoint blockade has significant activity in the palliative setting in patients with recurrent or metastatic cSCC. This single arm phase 2 prospective study aims to investigate the combination of curative intent chemoradiation and durvalumab (anti-PD-L1 checkpoint inhibitor) for this patient cohort. Our hypothesis is that >70% of patients with locally-advanced primary disease or regional metastases can be safely treated for cure using ChemoRadiation and ImmunOtherapy (CRIO) compared to the null hypothesis of ≤50%. Methods: Patients with unresectable locally and or regionally advanced pathologically confirmed cSCC deemed suitable for CRIO by consensus of the Head and Neck Multidisciplinary meeting will be eligible. We aim to accrue a total of 15 patients. The co-primary endpoints of CRIO will be the safety of treatment and the complete response rate. Secondary endpoints will include overall survival, progression free survival, and locoregional control. Translational research endpoints including biomarkers will also be explored utilising multiplex immunohistochemistry on tumour biopsy samples obtained prior to commencing treatment and during treatment (week 2). In addition, the utility of CXCR-4 PET scan will be explored.Discussion: CRIO is a novel trial evaluating the combination of curative intent chemoradiotherapy with concurrent durvalumab for patients with inoperable locally advanced cSCC.Trial registration Trial registered with the Australian New Zealand Clinical Trial Registry (ACTRN12618001573246)


Head & Neck ◽  
2017 ◽  
Vol 39 (7) ◽  
pp. 1462-1469 ◽  
Author(s):  
Bruce G. Ashford ◽  
Jonathan Clark ◽  
Ruta Gupta ◽  
N. Gopalakrishna Iyer ◽  
Bing Yu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document